AVXL · Anavex Life Sciences Corp.
Market Cap
$265.11M
Shares
92.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer and Director | $2,783,700 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $402,227 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer and Director | $3,894,453 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $501,058 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer and Director | $6,753,643 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $452,503 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer, and Director | $9,417,057 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $882,614 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer, and Director | $1,841,048 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $295,218 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer, and Director | $3,380,039 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $224,560 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Dr. Christopher Missling | President, Chief Executive Officer, and Director | $2,549,889 |
| Sandra Boenisch | Principal Financial Officer and Treasurer | $232,069 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Terrie Kellmeyer, PhD | Interim Chief Executive Officer | Appointed | 2026-05-06 |
| Christopher Missling, PhD | Chief Executive Officer | Terminated | 2026-05-06 |